King Faisal Specialist Hospital and Research Centre Celebrates the Success of Treating 100 Patients with Lymphocytic Leukemia Using CAR T-Cells
RIYADH, Saudi Arabia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- In a new step that offers cancer patients a glimmer of hope and a lifeline, the King Faisal Specialist Hospital and Research Centre (KFSH&RC) celebrated its success in treating the 100th patient with lymphoid leukemia using Chimeric Antigen Receptor T-cell (CAR T-cell) therapy. This aligns with KFSH&RC’s vision to be the optimal choice for specialized healthcare.
CAR T-cell therapy is an innovative treatment that enhances the ability of T-cells to recognize and destroy cancer cells after genetic modification in the laboratory to improve their targeting ability. This approach overcomes the challenge of distinguishing between cancer and normal cells, offering a promising method for treating lymphoid leukemia.
KFSH&RC emphasized that this innovative technology provides hope for patients with resistant leukemia and lymphoid tumors, especially those not effectively treatable with traditional methods.
As a strategic healthcare partner, KFSH&RC is sharing information about CAR T-cell therapy, its positive impact on healthcare improvement, and various healthcare solutions and innovations during the Global Health Exhibition taking place in Riyadh from October 29th to 31st.
KFSH&RC Hospital explained that this advanced therapy consists of four stages: extracting blood from the patient to obtain specific cells, then genetically modifying them in the lab for 3-4 weeks.
Shortly before CAR T-cell therapy, the patient receives a low dose of chemotherapy to enhance its effectiveness and the body's ability to fight cancer. Afterward, CAR T-cells are infused into the patient's arm, which is closely monitored for four weeks to ensure the body's adaptation.
The application of this advanced treatment in the Kingdom represents a qualitative addition to specialized medical care, reducing the financial, social, and health burdens of sending such cases abroad, aligning with Saudi Vision 2030 and its healthcare objectives.
King Faisal Specialist Hospital and Research Centre is globally recognized for offering this advanced form of treatment, thanks to its comprehensive therapeutic program featuring highly skilled medical, nursing, pharmaceutical, laboratory, and social specialists supported by an integrated infrastructure.
KFSH&RC is a global leader in specialized healthcare, innovation, advanced research, and medical education. It aims to develop medical technologies and elevate the standard of healthcare worldwide through partnerships with leading local, regional, and international institutions in clinical, research, and educational fields.
Contact information:
kfshrc@mcsaatchi.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9693817f-f8f6-4535-b14c-41f6801f16f7
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Scatec at COP28: Accelerating renewable energy transition from Egypt to South Africa2.12.2023 14:01:22 CET | Press release
Dubai, 2 December 2023: This week, Scatec ASA, a leading renewable energy company, is actively engaging in the UN Climate Change Conference in Dubai (COP28). Our focus is to underscore renewable energy as an unequivocal solution to climate change and emphasise the critical need for increased green energy investments in emerging markets. COP28 serves as a pivotal platform for global stakeholders to reinforce commitments aimed at averting catastrophic consequences of climate change. Scatec aligns with climate experts in stressing the urgency of the situation and the imperative to continue advancing towards the objectives outlined in the Paris Agreement. There's no time to waste, and collective progress is crucial for safeguarding our planet's future. “We are at COP28 to highlight the key role renewable energy must play in our energy future, "At COP28, our focus is on underscoring the crucial role renewable energy must assume in shaping our energy future, particularly in emerging markets,
Unplugged Performance Introduces UP INVINCIBLE®: A Game-Changer for Tesla Cybertruck Enthusiasts2.12.2023 05:06:20 CET | Press release
HAWTHORNE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Unplugged Performance, the industry leader in performance upgrades for Tesla vehicles, debuts a new chapter in Tesla tuning with the arrival of their UP INVINCIBLE® product line. UP INVINCIBLE® is tailored exclusively for Tesla Cybertruck owners who want to push the limits of on-road and off-road performance. The unveiling took place at Unplugged Performance’s celebratory afterparty for Tesla's highly anticipated Cybertruck delivery event on November 30th. Hosted at the company's headquarters in Hawthorne, California, neighboring Tesla Design Studio, SpaceX, and Starlink, the event drew a capacity crowd, reflecting the immense enthusiasm for this innovative product range. UP INVINCIBLE® represents a concerted effort to harness and amplify the rugged DNA of the Cybertruck, making it even more robust and capable in a variety of challenging environments. During the event, Ben Schaffer, CEO of Unplugged Performance, presented an extensiv
Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA2.12.2023 04:39:35 CET | Press release
SHANGHAI, China, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Therapeutic Goods Administration of the Australian Government Department of Health and Aged Care (TGA) has accepted the New Chemical Entity (NCE) application for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Additionally, the TGA has also granted an orphan drug designation to toripalimab for the treatment of NPC. This NCE application was submitted through Project Orbis, an initiative of
Terra Balcanica Announces Private Placement Financing1.12.2023 23:00:00 CET | Press release
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA) announces the intent to complete a non-brokered, private placement (“Private Placement”) for gross proceeds of up to $150,000 through the issuance of up to 3,750,000 common shares (“Common Shares”) at a purchase price of $0.04 per share. The Common Shares will be offered by way of prospectus exemptions in Canada and the Common Shares sold in the Private Placement will be subject to a hold period of four months plus one day. The Closing Date is expected to occur on or about December 11th, 2023, subject to regulatory approvals, including the approval by the CSE and certain other customary conditions including, but not limited to, execution of subscription agreements between the Company and the subscribers. The Private Placement will be utilized for opportuniti
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC1.12.2023 19:00:00 CET | Press release
Regulated Information Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtu